Gu-Shun Lai1, Jian-Ri Li2,3,4, Shian-Shiang Wang2,3,5, Chuan-Shu Chen2,3, Chun-Kuang Yang2, Sheng-Chun Hung2,3, Chen-Li Cheng2,3, Yen-Chuan Ou3,6, Kun-Yuan Chiu7,5. 1. Division of Urology, Department of Surgery, Chiayi Branch, Taichung Veterans General Hospital, Chiayi, Taiwan, R.O.C. 2. Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. 3. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C. 4. Department of Medicine and Nursing, Hungkuang University, Taichung, Taiwan, R.O.C. 5. Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, R.O.C. 6. Department of Urology, Tung's Taichung MetroHarbor Hospital, Taichung, Taiwan, R.O.C. 7. Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. chiu37782002@yahoo.com.
Abstract
AIM: To evaluate the oncological outcomes of pathological T3a upstaging from clinical T1 renal cell carcinoma. PATIENTS AND METHODS: We retrospectively studied patients who underwent radical or partial nephrectomy for clinical T1 renal tumors. RESULTS: The median follow-up period was 44 months. At three and five years, the respective overall survival rate was 88.7% and 82.4% in pT3a disease, 95.7% and 93.4% in pT1 (p=0.008), the cancer-specific survival rate, 93.9% and 90.8% in pT3a, 99% and 97.7% in pT1 (p=0.001), and the recurrence-free survival rate, 79.7% and 71.0% in pT3a, and 95.5 and 94.3% in pT1 (p<0.001). CONCLUSION: Patients with pathological T3a upstaging tumors were associated with a significantly decreased survival rate, along with a higher recurrence rate when compared to those with pathological T1 disease. Copyright
AIM: To evaluate the oncological outcomes of pathological T3a upstaging from clinical T1renal cell carcinoma. PATIENTS AND METHODS: We retrospectively studied patients who underwent radical or partial nephrectomy for clinical T1renal tumors. RESULTS: The median follow-up period was 44 months. At three and five years, the respective overall survival rate was 88.7% and 82.4% in pT3a disease, 95.7% and 93.4% in pT1 (p=0.008), the cancer-specific survival rate, 93.9% and 90.8% in pT3a, 99% and 97.7% in pT1 (p=0.001), and the recurrence-free survival rate, 79.7% and 71.0% in pT3a, and 95.5 and 94.3% in pT1 (p<0.001). CONCLUSION:Patients with pathological T3a upstaging tumors were associated with a significantly decreased survival rate, along with a higher recurrence rate when compared to those with pathological T1 disease. Copyright
Authors: William W Roberts; Sam B Bhayani; Mohamad E Allaf; Theresa Y Chan; Louis R Kavoussi; Thomas W Jarrett Journal: J Urol Date: 2005-03 Impact factor: 7.450
Authors: Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo Journal: J Urol Date: 2009-08-14 Impact factor: 7.450
Authors: Robert J Motzer; Eric Jonasch; Neeraj Agarwal; Sam Bhayani; William P Bro; Sam S Chang; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Mayer Fishman; Thomas H Gallagher; John L Gore; Steven L Hancock; Michael R Harrison; Won Kim; Christos Kyriakopoulos; Chad LaGrange; Elaine T Lam; Clayton Lau; M Dror Michaelson; Thomas Olencki; Phillip M Pierorazio; Elizabeth R Plimack; Bruce G Redman; Brian Shuch; Brad Somer; Guru Sonpavde; Jeffrey Sosman; Mary Dwyer; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2017-06 Impact factor: 11.908
Authors: Varun Sundaram; Robert S Figenshau; Timur M Roytman; Adam S Kibel; Robert L Grubb; Arnold Bullock; Brian M Benway; Sam B Bhayani Journal: Urology Date: 2011-03-16 Impact factor: 2.649
Authors: John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Christopher M Russell; Amir H Lebastchi; Juan Chipollini; Adam Niemann; Rohit Mehra; Todd M Morgan; David C Miller; Ganesh S Palapattu; Khaled S Hafez; Wade J Sexton; Philippe E Spiess; Alon Z Weizer Journal: Urology Date: 2018-04-17 Impact factor: 2.649
Authors: Melissa H W Tay; Thomas P Thamboo; Fiona M W Wu; Chen Zhaojin; Tai Bee Choo; Lata Ramaan; Ho Yee Tiong Journal: J Endourol Date: 2014-06-24 Impact factor: 2.942
Authors: Jasmir G Nayak; Premal Patel; Olli Saarela; Zhihui Liu; Anil Kapoor; Antonio Finelli; Simon Tanguay; Ricardo Rendon; Ron Moore; Peter C Black; Louis Lacombe; Rodney H Breau; Jun Kawakami; Darrel E Drachenberg Journal: Urology Date: 2016-03-31 Impact factor: 2.649
Authors: Paras H Shah; Daniel M Moreira; Zhamshid Okhunov; Vinay R Patel; Sameer Chopra; Aria A Razmaria; Manaf Alom; Arvin K George; Oksana Yaskiv; Michael J Schwartz; Mihir Desai; Manish A Vira; Lee Richstone; Jaime Landman; Arieh L Shalhav; Inderbir Gill; Louis R Kavoussi Journal: J Urol Date: 2016-02-19 Impact factor: 7.600